Gemcitabine, Docetaxel, and Capecitabine in Treating Patients With Cancer of Unknown Primary Origin
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, docetaxel, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving gemcitabine together with docetaxel and capecitabine works in treating patients with cancer of unknown primary origin.
Carcinoma of Unknown Primary
Drug: gemcitabine hydrochloride
Procedure: positron emission tomography
|Study Design:||Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Carcinoma Unknown Primary: Treatment With Gemcitabine, Docetaxel and Capecitabine (GTX) an Evaluation and Treatment Study of The Cancer Institute of New Jersey Oncology Group|
|Study Start Date:||July 2004|
|Study Completion Date:||July 2005|
|Primary Completion Date:||July 2005 (Final data collection date for primary outcome measure)|
- Determine the feasibility of positron emission tomography (PET) and pathology assessment in identifying the primary tumor site in patients with carcinoma of unknown primary.
- Determine the efficacy and safety of gemcitabine, docetaxel, and capecitabine in patients with carcinoma of unknown primary.
- Determine the frequency with which PET scan and pathology assessment can define the organ of origin in these patients.
OUTLINE: This is a 2-part, multicenter study.
- Part 1: Patients undergo a comprehensive standard evaluation, including pathologic assessment and positron emission tomography scan, to attempt to identify the primary tumor site. If the primary tumor site is identified, the patient proceeds to appropriate treatment for that tumor off study. If the primary tumor site remains unknown, the patient proceeds to chemotherapy in part 2 of the study.
- Part 2: Patients receive gemcitabine IV and docetaxel IV over 30 minutes on days 4 and 11. Patients also receive oral capecitabine twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed for 4 weeks and then every 6 months for 2 years.
PROJECTED ACCRUAL: Approximately 44 patients (10-29 for part 2) will be accrued for this study.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00119314
|United States, New Jersey|
|Cancer Institute of New Jersey at Hamilton|
|Hamilton, New Jersey, United States, 08690|
|Cancer Center at the Mountainside Hospital|
|Montclair, New Jersey, United States, 07042|
|Carol G. Simon Cancer Center at Morristown Memorial Hospital|
|Morristown, New Jersey, United States, 07962|
|Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School|
|New Brunswick, New Jersey, United States, 08903|
|Hematology and Oncology Group|
|Somerset, New Jersey, United States, 08873|
|Summit, New Jersey, United States, 07902-0220|
|Principal Investigator:||Elizabeth A. Poplin, MD||Rutgers Cancer Institute of New Jersey|